Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (TDAC) is a blank-check company organized to pursue an acquisition in the life sciences and healthcare sector, with its name reflecting a focus on the translational medicine and biopharmaceutical space. The company filed an 8-K with the Securities and Exchange Commission on July 27, 2026, reporting a material corporate event in its deal lifecycle. As a special purpose acquisition vehicle, TDAC is structured to identify and combine with a target operating at the interface of scientific research and clinical application. For complete data on TDAC's sponsor, IPO year, filing history, and current deal status, sign up for full access on SpacDesk.